Use of bisphosphonates for the treatment of metastatic bone pain. A survey of palliative physicians in the UK

Abstract

A postal survey of palliative physicians in the UK conducted in 1999 demonstrated widespread use of bisphosphonates for treatment of bone metastases from a variety of tumour types. In the absence of clear guidelines, however, there was found to be wide variation in treatment regimes, and opinions about efficacy varied greatly between respondents. Pamidronate was the most popular choice of drug, but a number of respondents chose to use clodronate, often on the basis of cost saving. A high level of uncertainty about how to monitor side-effects and efficacy was revealed. As well as acute treatment of severe pain, a significant number of respondents reported treating patients prophylactically, and the majority thought that their use of bisphosphonates would increase over the next 2 years. The potential financial consequences of this are considered.

Keywords

bisphosphonates bone metastases survey palliative care

Get full access to this article

View all access options for this article.

References

Herrala J , Puolijoki H , Liipo K et al. Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients. Bone 1998; 22: 577–582.

Diel IJ , Solomayer EF , Costa SD et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357–363.

Derenne S , Amiot M , Barille S et al. Zolendronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 1999; 14: 2048–2056.

British Association of Surgical Oncology Guidelines . The management of metastatic bone disease in the United Kingdom. Eur J Surg Oncol 1999; 25: 3–23.

Body JJ , Bart R , Burhardt P et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 1998; 16: 3890–3899.

Kylmala T , Taube T , Tammela TL et al. Concomitant iv and oral clodronate in the relief of bone pain–a double blind placebo-controlled study in patients with prostate cancer. Br J Cancer 1997; 76: 939–942.

Adami S , Mian M . Clodronate therapy of metastatic bone disease in patients with prostate carcinoma. Recent Results Cancer Res 1989; 116: 67–72.

Pelger RC , Hamdy MA , Zwinderman AH , Lycklama a Nijeholt AA , Papapoulos SE . Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone 1998; 22: 403–408.

Cascinu S , Graziano F , Alessandroni P et al. Different doses of pamidronate in patients with painful osteolytic bone metastases. Support Care Cancer 1998; 6: 139–143.

10.

Walker P , Watanabe S , Lawlor P , Hanson J , Pereira J , Bruera E . Subcutaneous clodronate: a study evaluating efficacy in hypercalcaemia of malignancy and local toxicity. Ann Oncol 1997; 8: 915–916.

11.

Lipton A . Bisphosphonates and breast carcinoma. Cancer Suppl 1997; 80: 1668–1673.